Chido Chinogurei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chido Chinogurei has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Andreas D. Haas
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
47 shared publications - Gary Maartens
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town
47 shared publications - Matthias Egger
Institute of Social and Preventive Medicine, University of Bern , Bern
47 shared publications - Naomi Folb
Affiliation Knowledge Translation Unit, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
47 shared publications - Yann Ruffieux
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
47 shared publications - Eliane Rohner
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
46 shared publications
Latest Publications
- 1 December 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (12) , 1344-1350
HIV Care Interruptions During the First Year of Antiretroviral Therapy Among Adolescents and Young Adults Living with HIV Aged 15–24 Years in Khayelitsha, South Africa
Background: Adolescents and young adults living with HIV (AYAHIV) aged 15–24 years experience poorer HIV outcomes than other age groups, with frequent interruptions from care. Interruptions during the first year of antiretroviral therapy (ART) are especially concerning, as they occur before sustained viral suppression. We estimated the incidence of early HIV care interruption and associated factors among AYAHIV initiating ART in the Khayelitsha cohort, Western Cape, South Africa. Methods: We conducted a retrospective cohort study of AYAHIV initiating ART between 2017 and 2021. Early HIV care interruption was defined as ≥90 days late for a scheduled refill without documented death or transfer. Participants were followed for 12–15 months. Cox proportional hazards models assessed associated factors, adjusting for age, sex, calendar year, dispensing interval (single-month vs multimonth), and regimen among 2020–2021 initiators. A sensitivity analysis was restricted to those with ≥4 refills. Results: Among 5149 AYAHIV (85% female; median age 23 years), 44% experienced early interruption, most within 6 months. Initiation in 2020 (adjusted hazard ratio [aHR]: 1.10, 95% confidence interval [95% CI]: 1.03 to 1.17) and 2021 (aHR: 1.28; 95% CI: 1.18 to 1.39) was associated with increased interruption risk versus 2017–2019. Dolutegravir was associated with a reduced risk compared with efavirenz (aHR: 0.87; 95% CI: 0.78 to 0.97). In sensitivity analyses (n = 3013), 32% interrupted, with similar associations. Conclusions: Early HIV care interruption was common, particularly during COVID-19. Dolutegravir was associated with improved retention, yet substantial early interruptions persisted, highlighting the need for intensified youth-focused support after ART initiation.
- 1 December 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (12) , 1344-1350
HIV Care Interruptions During the First Year of Antiretroviral Therapy Among Adolescents and Young Adults Living with HIV Aged 15–24 Years in Khayelitsha, South Africa
Background: Adolescents and young adults living with HIV (AYAHIV) aged 15–24 years experience poorer HIV outcomes than other age groups, with frequent interruptions from care. Interruptions during the first year of antiretroviral therapy (ART) are especially concerning, as they occur before sustained viral suppression. We estimated the incidence of early HIV care interruption and associated factors among AYAHIV initiating ART in the Khayelitsha cohort, Western Cape, South Africa. Methods: We conducted a retrospective cohort study of AYAHIV initiating ART between 2017 and 2021. Early HIV care interruption was defined as ≥90 days late for a scheduled refill without documented death or transfer. Participants were followed for 12–15 months. Cox proportional hazards models assessed associated factors, adjusting for age, sex, calendar year, dispensing interval (single-month vs multimonth), and regimen among 2020–2021 initiators. A sensitivity analysis was restricted to those with ≥4 refills. Results: Among 5149 AYAHIV (85% female; median age 23 years), 44% experienced early interruption, most within 6 months. Initiation in 2020 (adjusted hazard ratio [aHR]: 1.10, 95% confidence interval [95% CI]: 1.03 to 1.17) and 2021 (aHR: 1.28; 95% CI: 1.18 to 1.39) was associated with increased interruption risk versus 2017–2019. Dolutegravir was associated with a reduced risk compared with efavirenz (aHR: 0.87; 95% CI: 0.78 to 0.97). In sensitivity analyses (n = 3013), 32% interrupted, with similar associations. Conclusions: Early HIV care interruption was common, particularly during COVID-19. Dolutegravir was associated with improved retention, yet substantial early interruptions persisted, highlighting the need for intensified youth-focused support after ART initiation.
- Open Access
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (6) , e0006572
Episodic memory trajectories of older adults with and without HIV: A longitudinal population-based study in rural South Africa
With the introduction of antiretroviral treatment (ART), life expectancy among people with HIV in South Africa has increased substantially. This ageing population faces age-related challenges, including cognitive decline. Yet, differences in cognitive trends between people with and without HIV remain poorly understood. We analyzed longitudinal data on 3,066 adults aged 40 + years in rural South Africa from the “Health and Aging in Africa: Longitudinal Studies in South Africa" (HAALSA) cohort. Using generalized estimating equations, we compared episodic memory trajectories over seven years (2014 – 2022) across three groups: (1) people without HIV, (2) people with HIV and suppressed viral load, and (3) people with HIV and unsuppressed viral load. Furthermore, we predicted episodic memory scores at yearly intervals. On average, the trend in episodic memory decline did not differ between people without HIV and people with HIV with suppressed or unsuppressed viral load. However, looking individually at yearly intervals revealed that participants without HIV experienced significantly steeper episodic memory decline compared to participants with HIV with suppressed viral load when controlling for individual-level characteristics. Consequently, over the seven-year period, participants without HIV progressed from having episodic memory comparable to those with suppressed viral load to levels similar to those with unsuppressed viral load. The slower episodic memory decline among virally suppressed people with HIV compared to those without HIV may reflect benefits from regular healthcare engagement or may also be a result of selective mortality. Our findings suggest that policymakers should: (1) intensify efforts to increase ART coverage and adherence among unsuppressed people with HIV; (2) implement targeted cognitive screening for at-risk individuals regardless of HIV status; (3) expand screening and treatment for conditions that contribute to cognitive decline; and (4) promote behaviors that may preserve cognitive function, particularly in resource-constrained settings. Further research on potential underlying mechanisms should be conducted.
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (6) , e0006572
Open AccessEpisodic memory trajectories of older adults with and without HIV: A longitudinal population-based study in rural South Africa
With the introduction of antiretroviral treatment (ART), life expectancy among people with HIV in South Africa has increased substantially. This ageing population faces age-related challenges, including cognitive decline. Yet, differences in cognitive trends between people with and without HIV remain poorly understood. We analyzed longitudinal data on 3,066 adults aged 40 + years in rural South Africa from the “Health and Aging in Africa: Longitudinal Studies in South Africa" (HAALSA) cohort. Using generalized estimating equations, we compared episodic memory trajectories over seven years (2014 – 2022) across three groups: (1) people without HIV, (2) people with HIV and suppressed viral load, and (3) people with HIV and unsuppressed viral load. Furthermore, we predicted episodic memory scores at yearly intervals. On average, the trend in episodic memory decline did not differ between people without HIV and people with HIV with suppressed or unsuppressed viral load. However, looking individually at yearly intervals revealed that participants without HIV experienced significantly steeper episodic memory decline compared to participants with HIV with suppressed viral load when controlling for individual-level characteristics. Consequently, over the seven-year period, participants without HIV progressed from having episodic memory comparable to those with suppressed viral load to levels similar to those with unsuppressed viral load. The slower episodic memory decline among virally suppressed people with HIV compared to those without HIV may reflect benefits from regular healthcare engagement or may also be a result of selective mortality. Our findings suggest that policymakers should: (1) intensify efforts to increase ART coverage and adherence among unsuppressed people with HIV; (2) implement targeted cognitive screening for at-risk individuals regardless of HIV status; (3) expand screening and treatment for conditions that contribute to cognitive decline; and (4) promote behaviors that may preserve cognitive function, particularly in resource-constrained settings. Further research on potential underlying mechanisms should be conducted.
- Open Access
- 13 June 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (8)
Laboratory test availability and user fees in routine HIV care: a global analysis in 42 countries
Background: Laboratory testing is critical for diagnosis and treatment management for people with HIV, but is costly. When HIV resources are constrained, even before recent disruptions in US funding for the global HIV response, user fees have been used for cost recovery. We describe availability and charging of user fees for routine HIV laboratory testing globally. Methods: Routine test availability and charging of user fees were examined via an HIV clinic survey conducted September 2020–March 2021; responses reflected clinical practices in 2019. HIV clinics came from 42 low-, middle-, and high-income countries from the International epidemiology Databases to Evaluate AIDS (IeDEA) global research consortium. Results: Across 199 clinics, on-site test availability was generally limited, reflecting constraints in routine test availability across health conditions more broadly. Over 90% of clinics did not report charging of user fees. A higher percentage reporting user fees were from middle-income countries and from countries receiving Global Fund or PEPFAR country support, which may reflect settings with ongoing health funding gaps. Conclusions: Availability and user fees for essential HIV-related laboratory tests were limited in 2019. Monitoring user fees may provide insights about how national health systems are responding to steep reductions in global donor funding.
- 13 June 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (8)
Open AccessLaboratory test availability and user fees in routine HIV care: a global analysis in 42 countries
Background: Laboratory testing is critical for diagnosis and treatment management for people with HIV, but is costly. When HIV resources are constrained, even before recent disruptions in US funding for the global HIV response, user fees have been used for cost recovery. We describe availability and charging of user fees for routine HIV laboratory testing globally. Methods: Routine test availability and charging of user fees were examined via an HIV clinic survey conducted September 2020–March 2021; responses reflected clinical practices in 2019. HIV clinics came from 42 low-, middle-, and high-income countries from the International epidemiology Databases to Evaluate AIDS (IeDEA) global research consortium. Results: Across 199 clinics, on-site test availability was generally limited, reflecting constraints in routine test availability across health conditions more broadly. Over 90% of clinics did not report charging of user fees. A higher percentage reporting user fees were from middle-income countries and from countries receiving Global Fund or PEPFAR country support, which may reflect settings with ongoing health funding gaps. Conclusions: Availability and user fees for essential HIV-related laboratory tests were limited in 2019. Monitoring user fees may provide insights about how national health systems are responding to steep reductions in global donor funding.
- Open Access
- 14 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e976-e983
Association of Immunodeficiency and HIV Viremia With Cervical Precancer and Cancer Risk Among Women With HIV in South Africa
Background: Women with human immunodeficiency virus-1 (HIV) (WWH) have a higher cervical cancer risk than women without HIV. The timing and extent to which HIV viremia and immunodeficiency contribute to cervical carcinogenesis remain incompletely understood. Methods: We conducted a cohort study using medical claims data from a South African HIV program (2011–2022) and calculated incidence rates of cervical precancer and cancer. Cox proportional hazards models assessed associations with CD4 cell count and HIV ribonucleic acid (RNA). We tested summary and point-in-time CD4 and HIV RNA measures with 6–36 months lag periods. Models were adjusted for age, calendar year, and antiretroviral therapy (ART) initiation; fully adjusted models included both CD4 count and HIV RNA. Results: Over 66 000 WWH contributed more than 300 000 person-years; 1202 WWH developed moderate dysplasia (incidence rate: 394/100 000 person-years), 1237 severe dysplasia (405/100 000 person-years), 211 carcinoma in situ (66/100 000 person-years), and 257 cervical cancer (70/100 000 person-years). Lower CD4 counts were strongly associated with higher rates of cervical dysplasia, carcinoma in situ, and cancer, independent of HIV RNA. Lowest CD4 count over 30 months was the most informative measure for cervical dysplasia while CD4 count lagged by 24 months was most informative for cervical cancer. Higher HIV RNA was associated with increased risk of precancer and cancer in models unadjusted for CD4 count, with associations attenuated after adjustment. Conclusions: Maintaining high CD4 counts and achieving viral suppression through early ART initiation, along with using CD4 cell count for risk stratification in cervical screening, may help improve cervical cancer prevention among WWH in South Africa.
- 14 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e976-e983
Open AccessAssociation of Immunodeficiency and HIV Viremia With Cervical Precancer and Cancer Risk Among Women With HIV in South Africa
Background: Women with human immunodeficiency virus-1 (HIV) (WWH) have a higher cervical cancer risk than women without HIV. The timing and extent to which HIV viremia and immunodeficiency contribute to cervical carcinogenesis remain incompletely understood. Methods: We conducted a cohort study using medical claims data from a South African HIV program (2011–2022) and calculated incidence rates of cervical precancer and cancer. Cox proportional hazards models assessed associations with CD4 cell count and HIV ribonucleic acid (RNA). We tested summary and point-in-time CD4 and HIV RNA measures with 6–36 months lag periods. Models were adjusted for age, calendar year, and antiretroviral therapy (ART) initiation; fully adjusted models included both CD4 count and HIV RNA. Results: Over 66 000 WWH contributed more than 300 000 person-years; 1202 WWH developed moderate dysplasia (incidence rate: 394/100 000 person-years), 1237 severe dysplasia (405/100 000 person-years), 211 carcinoma in situ (66/100 000 person-years), and 257 cervical cancer (70/100 000 person-years). Lower CD4 counts were strongly associated with higher rates of cervical dysplasia, carcinoma in situ, and cancer, independent of HIV RNA. Lowest CD4 count over 30 months was the most informative measure for cervical dysplasia while CD4 count lagged by 24 months was most informative for cervical cancer. Higher HIV RNA was associated with increased risk of precancer and cancer in models unadjusted for CD4 count, with associations attenuated after adjustment. Conclusions: Maintaining high CD4 counts and achieving viral suppression through early ART initiation, along with using CD4 cell count for risk stratification in cervical screening, may help improve cervical cancer prevention among WWH in South Africa.
- Open Access
- 12 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (12) , ofaf693
Immunodeficiency, HIV Viremia, and Incident Anal Cancer Among People With HIV in South Africa
Among 130 992 people with HIV (PWH) in South Africa, 60 anal cancers were diagnosed. Lower CD4 counts and, to a lesser extent, higher HIV RNA viral loads were associated with an increased anal cancer risk. Maintaining high CD4 counts may contribute to anal cancer prevention among PWH in South Africa.
- 12 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (12) , ofaf693
Open AccessImmunodeficiency, HIV Viremia, and Incident Anal Cancer Among People With HIV in South Africa
Among 130 992 people with HIV (PWH) in South Africa, 60 anal cancers were diagnosed. Lower CD4 counts and, to a lesser extent, higher HIV RNA viral loads were associated with an increased anal cancer risk. Maintaining high CD4 counts may contribute to anal cancer prevention among PWH in South Africa.
- Open Access
- 26 September 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (9) , e1004765
Incidence and prognostic factors of self-harm and subsequent unnatural death in South Africa: A cohort study
Background: Self-harm is a major public health concern globally and in South Africa. Individuals with a history of self-harm are at increased risk of unnatural death, including suicide and fatal accidents. This study investigates the incidence and predictors of self-harm and its role as a predictor for subsequent unnatural death. Methods and findings: We conducted a cohort study using insurance claims and vital registration data from beneficiaries of South African medical insurance schemes (2011–2022), aged 10 years or older. We estimated the cause-specific cumulative incidences of healthcare encounters for intentional self-harm (International Classification of Diseases 10th Revision [ICD-10] codes X60-X84) and unnatural deaths (ICD-10 codes V01-Y98), using the Aalen–Johansen method. We assessed predictors of both outcomes using Cox regression. We followed 1,356,119 beneficiaries (median age 33 years, 52.2% female) for a median of 3 years, during which 7,510 (0.6%) had a healthcare encounter for self-harm. The 5-year cumulative incidence of self-harm ranged from 0.2% in males aged 10–14 to 2.1% in females aged 15–24. Sex, age, and mental disorders were strong predictors for self-harm, while HIV was a modest predictor. Among individuals who survived a self-harm event, the five-year cumulative incidence of subsequent unnatural death was 3.43% (95% CI [2.38, 4.76]) for males and 0.77% (95% CI [0.48, 1.19]) for females. Non-fatal self-harm was a strong predictor of subsequent unnatural death in both males (hazard ratio [HR] 7.03, 95% CI [5.27, 9.39]) and females (HR 4.63, 95% CI [3.00, 7.15]). The study’s main limitations include potential under-ascertainment of self-harm incidence due to reliance on routine data, and the unavailability of the exact cause of death, preventing analysis of suicide. Conclusion: Self-harm is common among beneficiaries of South African private medical insurance, with the highest risk in young females and individuals with mental disorders. These groups may benefit from targeted screening and early intervention. Non-fatal self-harm was a strong predictor of subsequent unnatural death, underscoring the need for suicide-specific brief interventions for individuals presenting with self-harm.
- 26 September 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (9) , e1004765
Open AccessIncidence and prognostic factors of self-harm and subsequent unnatural death in South Africa: A cohort study
Background: Self-harm is a major public health concern globally and in South Africa. Individuals with a history of self-harm are at increased risk of unnatural death, including suicide and fatal accidents. This study investigates the incidence and predictors of self-harm and its role as a predictor for subsequent unnatural death. Methods and findings: We conducted a cohort study using insurance claims and vital registration data from beneficiaries of South African medical insurance schemes (2011–2022), aged 10 years or older. We estimated the cause-specific cumulative incidences of healthcare encounters for intentional self-harm (International Classification of Diseases 10th Revision [ICD-10] codes X60-X84) and unnatural deaths (ICD-10 codes V01-Y98), using the Aalen–Johansen method. We assessed predictors of both outcomes using Cox regression. We followed 1,356,119 beneficiaries (median age 33 years, 52.2% female) for a median of 3 years, during which 7,510 (0.6%) had a healthcare encounter for self-harm. The 5-year cumulative incidence of self-harm ranged from 0.2% in males aged 10–14 to 2.1% in females aged 15–24. Sex, age, and mental disorders were strong predictors for self-harm, while HIV was a modest predictor. Among individuals who survived a self-harm event, the five-year cumulative incidence of subsequent unnatural death was 3.43% (95% CI [2.38, 4.76]) for males and 0.77% (95% CI [0.48, 1.19]) for females. Non-fatal self-harm was a strong predictor of subsequent unnatural death in both males (hazard ratio [HR] 7.03, 95% CI [5.27, 9.39]) and females (HR 4.63, 95% CI [3.00, 7.15]). The study’s main limitations include potential under-ascertainment of self-harm incidence due to reliance on routine data, and the unavailability of the exact cause of death, preventing analysis of suicide. Conclusion: Self-harm is common among beneficiaries of South African private medical insurance, with the highest risk in young females and individuals with mental disorders. These groups may benefit from targeted screening and early intervention. Non-fatal self-harm was a strong predictor of subsequent unnatural death, underscoring the need for suicide-specific brief interventions for individuals presenting with self-harm.
- Open Access
- 29 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf537
Anal Cancer Incidence Rates Among Men and Women With and Without HIV in South Africa
Background: More than 7.5 million people in South Africa have HIV, but little is known about the association of HIV and anal cancer incidence. We examined anal cancer incidence in a large South African cohort of insured men and women. Methods: We conducted a cohort study using reimbursement claims data from a South African medical insurance scheme (01/2011-07/2020) to assess anal cancer rates among people with and without HIV aged ≥18 years. We estimated adjusted hazard ratios (aHRs) for the association of HIV and incident anal cancer using flexible parametric survival models. Covariates included sex, age, calendar year, a history of genital warts and other sexually transmitted infections, and in women, cervical precancer. Results: We included 1 068 915 people of whom 69 985 (7%) were living with HIV. Over 3 933 145 person-years, 122 anal cancers were diagnosed (crude rate: 3.1/100 000 person-years; 95% confidence intervals [CI] 2.6–3.7). People with HIV had a 4-fold higher anal cancer risk than people without HIV (aHR 4.43; 95% CI 2.44–8.04). While anal cancer rates were similar among men and women, older age (≥65 vs 45–54 years; aHR 5.01; 95% CI: 2.94–8.53), a history of genital warts (aHR 7.56; 95% CI: 2.28–25.07), and among women, a prior cervical precancer diagnosis (aHR 5.70; 95% CI 1.75–18.58) were associated with a higher anal cancer risk. Conclusions: In South Africa, men and women with HIV, older individuals, people with a history of genital warts, and women with a prior cervical precancer diagnosis might benefit from prioritized access to anal cancer screening.
- 29 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf537
Open AccessAnal Cancer Incidence Rates Among Men and Women With and Without HIV in South Africa
Background: More than 7.5 million people in South Africa have HIV, but little is known about the association of HIV and anal cancer incidence. We examined anal cancer incidence in a large South African cohort of insured men and women. Methods: We conducted a cohort study using reimbursement claims data from a South African medical insurance scheme (01/2011-07/2020) to assess anal cancer rates among people with and without HIV aged ≥18 years. We estimated adjusted hazard ratios (aHRs) for the association of HIV and incident anal cancer using flexible parametric survival models. Covariates included sex, age, calendar year, a history of genital warts and other sexually transmitted infections, and in women, cervical precancer. Results: We included 1 068 915 people of whom 69 985 (7%) were living with HIV. Over 3 933 145 person-years, 122 anal cancers were diagnosed (crude rate: 3.1/100 000 person-years; 95% confidence intervals [CI] 2.6–3.7). People with HIV had a 4-fold higher anal cancer risk than people without HIV (aHR 4.43; 95% CI 2.44–8.04). While anal cancer rates were similar among men and women, older age (≥65 vs 45–54 years; aHR 5.01; 95% CI: 2.94–8.53), a history of genital warts (aHR 7.56; 95% CI: 2.28–25.07), and among women, a prior cervical precancer diagnosis (aHR 5.70; 95% CI 1.75–18.58) were associated with a higher anal cancer risk. Conclusions: In South Africa, men and women with HIV, older individuals, people with a history of genital warts, and women with a prior cervical precancer diagnosis might benefit from prioritized access to anal cancer screening.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Table S9 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S9 shows hazard ratios for prostate cancer diagnosis, with no left-truncation at first HIV indicator.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S9 shows hazard ratios for prostate cancer diagnosis, with no left-truncation at first HIV indicator.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S5 shows characteristics at diagnosis of prostate cancer, by population group.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S5 shows characteristics at diagnosis of prostate cancer, by population group.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Cohort characteristics by HIV status and overall.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Cohort characteristics by HIV status and overall.